AOD 9604 differs from full-length growth hormone and GHRH analogues in that it does not activate the growth hormone receptor or stimulate endogenous GH release
Key limitations of current evidence include: Relatively short follow-up periods (typically 35 years) in randomised trials, whereas pancreatic cancer may take years to develop Potential for detection bias, as patients on GLP-1 therapy may undergo more frequent medical monitoring Difficulty accounting for all confounding factors in observational studies Despite these limitations, the weight of current evidence does not support a causal link between GLP-1 receptor agonist use and pancreatic cancer development
Compared to 47 pounds in the diet-only control group
In vitro and in vivo laboratory studies have examined its interactions with fibroblasts, tendon cells, and ligament tissue in controlled research models
And the need to escape and the need to process things or confront things indirectly was probably solidified by that trauma. Most of his career, though, has been about inhabiting trauma, so much so that I half expect his IMDb page to be spattered with blood
